Go on the Offensive Against Colorectal Cancer

Immuno-oncology regimens were linked with improved long-term survival among patients with hepatocellular carcinoma.

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

It is essential to continue to develop and incorporate educational strategies to increase screening for colorectal cancer in our communities.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The median disease-free survival with GVAX vaccine plus low-dose cyclophosphamide; GVAX plus cyclophosphamide and nivolumab; and GVAX plus cyclophosphamide, nivolumab, and urelumab, was 13.90 months, 26.1 months, and 31.6 months, respectively.

The FDA has approved the therascreen PDGFRA kit to identify patients with gastrointestinal stromal tumors who may benefit from treatment with avapritinib.